Cycuria is a preclinical-stage oncology startup based in Graz, Austria, founded by scientists from the Medical University of Graz, TU Munich and the University of Heidelberg. We are pioneering a novel protein-based targeted therapy for hematological cancers and beyond. Our approach selectively targets tumor and tumor stem cells while preserving healthy hematopoiesis and physiology, enabling durable efficacy without dose-limiting toxicity and offering a transformative new treatment paradigm.